These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) will likely be announcing its earnings results before the market opens on ...

Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) was upgraded by Raymond James from an “outperform” rating to a “strong-buy ...

New Haven, Connecticut Tuesday, March 11, 2025, 18:00 Hrs [IST] ...

Trevi Therapeutics, Inc.’s TRVI share price has surged by 41.16%, which has investors questioning if this is right time to sell.

Trevi Therapeutics (Nasdaq: TRVI) reported promising results from a mid-stage study of its experimental chronic cough ...

Under the terms of the agreement, Redfin shareholders will receive 0.7926 shares of Rocket Class A common stock for each Redfin share—a 63% premium over Redfin’s 30-day volume-weighted average price.

Fintel reports that on March 10, 2025, Raymond James upgraded their outlook for Trevi Therapeutics (NasdaqGM:TRVI) from ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) ...

The New Haven, Conn., biopharmaceutical company shared positive topline results from a Phase 2a trial of Haduvio for the treatment of patients with refractory chronic cough. Haduvio met the primary ...

Trevi Therapeutics (TRVI) surges 40% premarket as Haduvio proves effective in reducing chronic coughing in trials.

US equity futures were falling ahead of Monday's opening bell as traders monitored developments surrounding US President Donald Trump's evolving trade policy amid reports of a possible slowing of the ...